Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part I: Pathogenesis;Mécanismes pathogéniques de la sclérodermie et leurs conséquences thérapeutiques. 1ère partie: Pathogénie

Revue Medicale Suisse

Volumn 2, Issue 62, 2006, Pages 1052-1057

  Zuber, Jean Philippe ^a   Chizzolini, Carlo ^b   Leimgruber, Annette ^a   Bart, Pierre Alexandre ^a   Spertini, François ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Service d'immunologie et d'allergologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; GENE ACTIVATION; HUMAN; HUMORAL IMMUNITY; INTESTINE; KIDNEY; LUNG; MICROCHIMERISM; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

FIBROSIS; HUMANS; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 33749166359     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
2. * Sakkas Li, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004;50: 1721-33.
3. Postlethwaite AE, Holness MA, Katai H, et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-85.
4. Kodera T, McGaha T, Phelps R, et al. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-β production by fibroblasts. Proc Natl Acad Sci USA 2002; 99:3800-5.
5. α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 2006;12:99-106.
6. Kurosawa K, Hirose K, Sano H, et al. Increased IL-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-3.
7. Distler JH, Jüngel A, Caretto D, et al. Monocyte chemoattractant protein I released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214-25.
8. Chizzolini C, Parel Y, De Luca C, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003;48:2593-604.
9. Sakkas LI, Xu B, Artlett CM, et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-59.
10. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998;338:1186-91.
11. Scaletti C, Vultaggio A, Bonifacio S, et al. Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 2002;46:445-50.
12. Sato S, Fujimoto M, Hasegawa M, et al. Altered blood B lymphocytes homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated B cells. Arthritis Rheum 2004;50:1918-27.
13. Chizzolini C, Raschi E, Rezzonico R, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002;46:1602-13.
14. Zhou X, Tan FK, Milewicz DM, et al. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-β pathway to recapitulate the «scleroderma phenotype». J Immunol 2005;175:4555-60.
15. Lunardi C, Dolcino M, Peterlana D, et al. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: A gene array approach. PLoS Med 2006;3:94-108.
16. Sgonc R, Gruschwitz M, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
17. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
18. Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364: 603-10.
19. Mayse MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190-9.
20. Shi-Wen X, Demon CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodelling: Role of endothelin-1. J Invest Dermatol 2001;116:417-25.
21. Massague J. Transforming growth factor-β family. Annu Rev Cell Biol 1990;6:597-641.
22. Ihn H, Yamane K, Kubo M, et al. Blockade of endogenous transforming growth factor β signalling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
23. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005;7: 156-62.
24. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
25. Takehara K. Pathogenesis of systemic sclerosis. J Rheumatol 2003;30:755-9.
26. Yamakage A, Kikuchi K, Smith EA, et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992;175:1227-34.